Pharmaceutical

Aquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the year ending December 31, 2017. As quoted in the press release: “We are excited to have completed enrollment in our LEADERSHIP 301 clinical trial …

Aquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the year ending December 31, 2017.

As quoted in the press release:

“We are excited to have completed enrollment in our LEADERSHIP 301 clinical trial of rosiptor in interstitial cystitis/bladder pain syndrome (IC/BPS), with the hope of showing that rosiptor demonstrates efficacy and tolerability in these patients,” said David Main, President & CEO of Aquinox. “We recognize that there is a great need for new treatment options in IC/BPS. We remain on track and anticipate releasing topline data in the third quarter of 2018.”

Click here to read the full press release.

MARKETS

Markets
TSX20165.43-104.54
TSXV658.96-10.61
DOW33900.19-251.82
S&P 5004262.69-42.51
NASD12895.32-207.23
ASX7105.40+41.10

COMMODITIES

Commodities
Gold1761.62-13.85
Silver19.73-0.40
Copper3.58-0.04
Palladium2141.00-4.00
Platinum922.00-12.00
Oil86.82+0.29
Heating Oil3.49+0.05
Natural Gas9.21-0.12

DOWNLOAD FREE REPORTS

×